Please ensure Javascript is enabled for purposes of website accessibility

How Big Is Bristol Myers Squibb's Latest FDA Approval?

By Keith Speights and Brian Orelli, PhD - Updated Jun 22, 2021 at 3:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's an important win for a drug gained in the Celgene acquisition to reach blockbuster status.

Bristol Myers Squibb (BMY -0.55%) recently picked up another U.S. Food and Drug Administration (FDA) approval for Zeposia in treating ulcerative colitis. In this Motley Fool Live video recorded on June 2, Motley Fool contributors Keith Speights and Brian Orelli discuss just how big this FDA win is for Bristol Myers Squibb.

Keith Speights: The FDA recently approved Bristol Myers Squibb's Zeposia. It's also known as ozanimod. This approval was for treating ulcerative colitis. This is Bristol Myers Squibb's first win in a gastrointestinal indication. Brian, how big is this for the company?

Brian Orelli: Yes. This is Celgene's old multiple sclerosis drug and it had some issues with the FDA. The FDA gave it a Refuse to File, you recall, because they had some issues with the breakdown products. They hadn't characterized the products that gets broken down once it goes into the humans. It did eventually get approved for multiple sclerosis in March of 2020.

Now in ulcerative colitis, I think it's going to have a lot of competition. There are quite a few drugs that are approved for that indication. There's three different TNF inhibitors; Remicade and Simponi from Johnson & Johnson, and Humira from AbbVie, and then Takeda and Johnson & Johnson also have other biologics that are approved for ulcerative colitis.

That's just the biologics. This is progressive disease, and patients would start on generic anti-inflammatory drug, and then move up maybe to small molecule branded drugs, something like Xeljanz from Pfizer.

I think between the competition and then also the class of drugs that Bristol Myers' drug is in has had some hard side effects. I think that's going to cause the drug probably to be a last-line treatment. I think that that could cause some serious problems in terms of getting any reasonable amount of sales from this drug.

Some doctors will use it, and it definitely worked in the clinical trials, although they only tested it against placebo. I think if they had tested it head-to-head against some other drug in the class and it had beat that drug, then you could see doctors rushing to it more. But right now, I think it'll probably be a wait-and-see and only use it in patients who aren't responding to a lot of the other drugs.

Speights: Back in the day before Celgene was acquired by Bristol Myers Squibb, Celgene was predicting that Zeposia, or at the time, ozanimod, could reach peak sales of $4 to $6 billion dollars. I don't think that rosy of an outlook is applicable, and now, for some of the reasons you just mentioned, Brian, you still think this drug might be a blockbuster for Bristol Myers Squibb?

Orelli: I think that probably between multiple sclerosis and ulcerative colitis, I think it probably could be a blockbuster, but certainly not coming out of the gate. It will probably be toward the end of its patent life, it could hit blockbuster status probably.

Brian Orelli, PhD has no position in any of the stocks mentioned. Keith Speights owns shares of AbbVie, Bristol Myers Squibb, and Pfizer. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$74.15 (-0.55%) $0.41
Pfizer Inc. Stock Quote
Pfizer Inc.
$48.58 (-1.40%) $0.69
Johnson & Johnson Stock Quote
Johnson & Johnson
$166.77 (-0.48%) $0.81
AbbVie Inc. Stock Quote
AbbVie Inc.
$141.29 (-0.11%) $0.15
Takeda Pharmaceutical Company Limited Stock Quote
Takeda Pharmaceutical Company Limited
$14.18 (-0.14%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.